Elkfork Partners LLC acquired a new position in shares of Quest Diagnostics Incorporated (NYSE:DGX) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm acquired 95,472 shares of the company’s stock, valued at approximately $8,774,000. Elkfork Partners LLC owned approximately 0.07% of Quest Diagnostics as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of DGX. Itau Unibanco Holding S.A. purchased a new position in shares of Quest Diagnostics during the third quarter worth about $110,000. TLP Group LLC purchased a new position in shares of Quest Diagnostics during the third quarter worth about $130,000. Pennsylvania Trust Co purchased a new position in shares of Quest Diagnostics during the third quarter worth about $204,000. Lakeview Capital Partners LLC purchased a new position in shares of Quest Diagnostics during the third quarter worth about $204,000. Finally, Schnieders Capital Management LLC purchased a new position in shares of Quest Diagnostics during the second quarter worth about $206,000. Hedge funds and other institutional investors own 87.71% of the company’s stock.

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Quest Diagnostics Incorporated (NYSE:DGX) traded down 0.27% on Friday, hitting $95.04. 336,191 shares of the stock traded hands. The company has a market cap of $13.02 billion, a price-to-earnings ratio of 21.07 and a beta of 0.68. The stock has a 50-day moving average price of $92.71 and a 200 day moving average price of $87.09. Quest Diagnostics Incorporated has a 1-year low of $65.06 and a 1-year high of $96.45.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings data on Thursday, January 26th. The company reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. The business earned $1.86 billion during the quarter, compared to analyst estimates of $1.86 billion. Quest Diagnostics had a net margin of 8.56% and a return on equity of 14.61%. The firm’s quarterly revenue was up .6% on a year-over-year basis. During the same quarter last year, the business earned $1.29 EPS. On average, analysts anticipate that Quest Diagnostics Incorporated will post $5.47 EPS for the current fiscal year.

“Elkfork Partners LLC Invests $8,774,000 in Quest Diagnostics Incorporated (DGX)” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/02/17/elkfork-partners-llc-invests-8774000-in-quest-diagnostics-incorporated-dgx.html.

A number of research analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating and set a $102.00 price objective for the company in a report on Tuesday, January 24th. Canaccord Genuity set a $90.00 price objective on shares of Quest Diagnostics and gave the company a “buy” rating in a report on Tuesday, January 17th. Goldman Sachs Group, Inc. (The) upgraded shares of Quest Diagnostics from a “neutral” rating to a “buy” rating and set a $102.00 price objective for the company in a report on Monday, December 12th. Barclays PLC set a $85.00 price objective on shares of Quest Diagnostics and gave the company a “hold” rating in a report on Monday, November 14th. Finally, Jefferies Group LLC boosted their price objective on shares of Quest Diagnostics from $86.00 to $96.00 and gave the company a “hold” rating in a report on Friday, January 27th. Three analysts have rated the stock with a sell rating, ten have issued a hold rating and three have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $90.38.

In related news, SVP Catherine T. Doherty sold 80,000 shares of the firm’s stock in a transaction that occurred on Monday, January 30th. The shares were sold at an average price of $90.58, for a total value of $7,246,400.00. Following the completion of the transaction, the senior vice president now owns 119,321 shares in the company, valued at approximately $10,808,096.18. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 1.50% of the stock is owned by company insiders.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Company’s Diagnostic Information Services business develops and delivers diagnostic testing information and services to patients, physicians, health plans, hospitals, accountable care organizations (ACOs), integrated delivery networks (IDNs), other commercial laboratories, employers and others.

5 Day Chart for NYSE:DGX

Receive News & Stock Ratings for Quest Diagnostics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Incorporated and related stocks with our FREE daily email newsletter.